Found: 1
Select item for more details and to access through your institution.
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
- Published in:
- Schizophrenia Bulletin, 2019, v. 45, n. 2, p. 350, doi. 10.1093/schbul/sby049
- By:
- Publication type:
- Article